SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions February patent applications/inventions, industry category 02/13

20130053301 - Dipeptide-based prodrug linkers for aliphatic amine-containing drugs: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with... Agent: Ascendis Pharma A/s

20130053302 - Treatment of sepsis using complement inhibitors: Methods for the treatment of sepsis with complement inhibitors are disclosed. In particular, C3 inhibitors, such as Compstatin and Compstatin analogs, are administered at various times following the onset of sepsis to alleviate tissue damage and organ failure, which are hallmarks of the second, extravascular stage of sepsis. Combination therapies... Agent:

20130053303 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Onyx Therapeutics, Inc.

20130053304 - Glucagon-like peptide-1 analogues and uses thereof: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine... Agent:

20130053305 - Peptide compounds that can be used as antibacterial agents: Compounds of formula (I), where: R0 is (C8-C11)-branched alkyl, CH3—(CH2)m—, CH3—O—(CH2CH2O)2CH2—, or phenyl-(CH2)x—; m=6-10; x=1-3; R1, R3, R4, R7, and R8 are independently selected from the formula GF-(CH2)n—; with n=1-4; and GF=—NH2 or —NH—C(═NH)—NH2; R2 is —CH(CH3)(OH), —CH(CH3)2, —CH2NH2 o —CH2OH; R5 and R6 are independently selected among H, —(C1-C4)—... Agent: Universidad De Barcelona

20130053306 - Use of histones for the early diagnosis and/or preventive therapy of virally-infected living cells and a biochip for carrying out said diagnosis: There is provided a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified after viral infection. The agent includes at least one component, selected from a group... Agent:

20130053307 - Method for weight loss aided by administration of human chorionic gonadotropin: Methods are provided for increased rates of weight loss while reducing the discomfort caused by dieting. An initial daily dose of HCG of 200 IU or greater is administered to a patient on a reduced calorie diet plan for weight loss. The reduced calorie diet plan includes limits on the... Agent:

20130053308 - 4-aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists: New 4-amino-pyrimidine derivatives as potent antagonists of the adenosine Aza receptor formula (I): (I) The invention provides as well a method for preparing such compounds, pharmaceutical compositions comprising an effective amount of these compounds and the use of such compounds in the manufacture of a medicament to treat pathological affections... Agent:

20130053309 - Substituted diketopiperazine analogs for use as drug delivery agents: Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents... Agent:

20130053310 - Novel glucagon analogues: The present invention relates to glucagon peptide agonists which have improved solubility and stability, to the use of the peptides in therapy, to methods of treatment comprising administration of the peptides to patients in need thereof, and to the use of the peptides in the manufacture of medicaments. The glucagon... Agent: Novo Nordisk A/s

20130053311 - Glp-1 analogues and derivatives: The invention relates to a GLP-1 analogue which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1 (7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten... Agent: Novo Nordisk A/s

20130053312 - Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes: A method of treating or preventing an ovary-related syndrome associated with infertility in a subject in need thereof is provided. The method comprising administering to the subject a pharmaceutical composition comprising an active ingredient consisting of pigment epithelium-derived factor (PEDF) and a pharmaceutically acceptable carrier, thereby treating or preventing the... Agent: Ramot At Tel-aviv University Ltd.

20130053313 - New formulation for increasing bioavailability of neurturin: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.... Agent: Develogen Aktiengesellschaft

20130053314 - Mutant epidermal growth factor polypeptides with improved biological activity and methods of their making and use: Compositions that are EGF polypeptides that possess improved biological activity as compared to the biological activity exhibited by wild-type EGF are provided. Also provided are methods for the preparation of these mutants, methods for the use of these mutants, methods for rationally designing new polypeptide mutants, and methods for screening... Agent:

20130053316 - Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist: The invention provides a method of treating a subject having, or at risk of developing, a condition in which functioning of the small or large intestine is impaired, enhancing functioning or preventing damage to the small or large intestine in a subject, or ameliorating inflammation of the small or large... Agent: Mount Sinai Hospital

20130053317 - Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection: The present invention provides methods for treating, preventing and/or ameliorating at least one cardiovascular disorder in a human in need thereof comprising administering to said human a pharmaceutical composition comprising at least one polypeptide having at least one GLP-1 activity and/or at least one GLP-1 agonist.... Agent: Glaxosmithkline LLC

20130053315 - Novel glp-1 derivatives: Novel polypeptide derivatives having protracted profile of action.... Agent: Novo Nordisk A/s

20130053318 - Modulating aquaporins with relaxin: The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.... Agent:

20130053319 - Chemokine derived peptides and uses for chronic wound and angiogenesis inhibition treatments: Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10)... Agent: Tuskegee University, Tuskegee Al And University Of Pittsburgh, Pittsburh, Pa

20130053320 - Treatment of anemia by adnp and adnf polypeptides: This invention relates to the use of ADNP, ADNP2, and ADNF polypeptides in the treatment of anemia and related conditions. Compositions of the ADNP, ADNP2, or ADNF polypeptides for such use are disclosed. Also provided are methods for concentrating or extracting ADNP, ADNP2, or ADNF polypeptides from dairy products and... Agent: Ramot At Tel-aviv University, Ltd.

20130053321 - Inhibitors of mitochondrial fission and methods of use thereof: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to,... Agent:

20130053322 - Hsa-related compositions and methods of use: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.... Agent: Medlmmune, LLC

20130053323 - Methods and use related to humanin and humanin-like peptides: The field of medical therapeutics, and more particularly to therapeutic peptides selectively active in the treatment of bone- or cartilage disorders. Provided herein are a series of humanin and humaninlike peptides, fragments, analogs, derivatives, and variants thereof, which have beneficial activities on cartilage tissues and/or bone tissues including the prevention... Agent:

20130053324 - Novel self-assembling peptides and their use in the formation of hydrogels: There is described a group of novel self-assembling peptides (SAPs), comprising biotinylated and unbiotinylated sequences, hybrid peptide-peptoid sequences, branched sequences for a total of 48 tested motifs, showing a heterogeneous ensemble of spontaneously self-assembled structures at the nano- and microscale, ranging from short tabular fibers to twisted ribbons, nanotubes and... Agent: Universita' Degli Studi Di Milano Bicocca

20130053325 - Secondary structure stabilized nmda receptor modulators and uses thereof: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.... Agent:

20130053326 - Method of treating sexual dysfunctions with delta opioid receptor agonist compounds: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.... Agent:

20130053327 - Polypeptide expressed in the stratum corneum and use thereof: A novel polypeptide isolated from the cornified envelope, polypeptides similar to the latter or fragments of the polypeptide as well as a cosmetic and/or pharmaceutical composition containing same are described. The mainly cosmetic and/or therapeutic use of the polypeptide, or similar polypeptides or fragments of the amino acid sequence of... Agent: Universite Paul Sabatier Toulouse Iii

20130053328 - Compositions and methods of inhibiting photoreceptor apoptosis: The present invention provides compositions and methods to prevent apoptosis. In particular, provided herein are compositions and methods which prevent FAS-mediated photoreceptor apoptosis.... Agent: The Regents Of The University Of Michigan

20130053329 - Methods of inhibiting apoptosis or inflammation in a mammal by administering an isolated bcl protein: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods... Agent: University Of Washington

20130053330 - Fertilization prediction and promotion: The outcome of an in vitro fertilization (IVF) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (HRG) gene or protein analysis of HRG. The proline isoform of HRG or an amino... Agent: Karolinska Institutet Innovations Ab

20130053331 - Sugar derivatives, methods for preparation thereof, their use as surface-active agents: e

20130053333 - Aminoquinoline derivatives: This invention relates to novel aminoquinoline derivatives of Formula (I) or Ia, or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an aminoquinoline derivative,... Agent:

20130053332 - Use: The present invention relates to a composition comprising a high glucosinolate Cruciferous vegetable (such as a high glucosinolate broccoli) having a high level of glucosinolate and/or at least one derivative thereof for use in the treatment or prevention of a cardiovascular disease or for use in promoting heart and/or cardiovascular... Agent: Plant Bioscience Limited

20130053334 - Monomers and oligonucleotides comprising cycloaddition adduct(s): The invention features compounds of formula (V) or(XII). In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.... Agent: Alnylam Pharmaceuticals, Inc.

20130053335 - Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine: Disclosed is a composition comprising a derivative of NDGA and 7-hydroxystaurosporine. The composition can be in a unit dose form or kit. Also disclosed are methods for achieving cytotoxicity, particularly of rapidly dividing cells such as cancer, by administering a composition of the invention. In various embodiments of the invention... Agent: The Johns Hopkins University

20130053336 - Treatment of chlamydiaceae infections by means of beta-lactams: The invention relates to a method for treating infections of bacteria of the Chlamydiaceae family using a β-lactam. The invention also relates to a method for treating diseases caused by an infection of bacteria of the Chlamydiaceae family using a β-lactam.... Agent: Centre National De La Recherche Scientifique (cnrs)

20130053337 - Guanidinylated aminoglycoside-lipid conjugates: Guanadinylated aminoglycoside-lipid conjugates are prepared. Such conjugates may comprise an aminoglycoside such as an aminoglyucoside antibiotic like neomycin or kanamycin, at least one guanidino group attached to a primary or secondary carbon atom of the aminoglyucoside group and at least one lipid group attached through a bond or a linker... Agent: University Of Manitoba

20130053426 - Composition for delivery of genetic material: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.... Agent:

20130053427 - Conjugate constructs, delivery, and use for treatment of disease: Pharmaceutical formulations of antisense peptide-conjugated phosphorodiamidate morpholino olgomers and methods of use for treatment of apicomplexan infections are disclosed. The invention is particularly directed to treatment of Toxoplasma gondii infections.... Agent:

20130053430 - Modulation of cetp expression: Provided herein are methods, compounds, and compositions for reducing expression of a CETP mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or HDL activity and reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and... Agent: Isis Pharmaceuticals, Inc.

20130053431 - Modulation of growth hormone receptor expression and insulin-like growth factor expression: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of... Agent: Antisense Therapeutics Limited

20130053428 - Natural antisense and non-coding rna transcripts as drug targets: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).... Agent: The Scripps Research Institute

20130053429 - Treatment of fibrosis using microrna 19b: The present invention provides a method for treating or preventing fibrosis comprising administering to a patient in need of such treatment or prevention an amount of microRNA-19b effective to treat or prevent said fibrosis. In some embodiments, the invention relates to inhibiting the activation of collagen-producing cells and thereby treating... Agent: The Charlotte-mecklenburg Hospital Authority D/b/a Carolinas Medical Center

20130053432 - In vivo gene sensors: Described are methods and compositions for the detection of target genes. The inventors have developed a synthetic nucleic acid sensor-effector gene circuit. In cells without a target gene, the circuit suppresses e.g., effector production, but in the presence of the target gene the suppression is subject to competition, such that... Agent: Trustees Of Boston University

20130053338 - Use of p2x purinergic receptor agonists to enhance insulin secretion in pancreatic beta cells: Pharmaceutical compositions containing P2X purinergic agonists, e.g. P2X3 agonists, for increasing insulin secretion in a subject, methods of use, and methods of screening for related compounds and agents.... Agent:

20130053340 - Intestinal barrier integrity: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.... Agent: N.v. Nutricia

20130053339 - Synergistic phytochemical composition and a process for preparation thereof: e

20130053342 - Hydroxylated amide skin moisturizer:

20130053341 - Therapeutic compounds and related methods of use: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit.... Agent:

20130053343 - Compounds and methods for inhibiting serotonin synthesis: Compounds having the structures below that are TPH1 inhibitors are provided: The compounds are useful of, e.g., to increase bone mass. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis.... Agent: The Trustees Of Columbia University In Th City Of

20130053344 - Synthesis of pyrrolidine compounds: Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.... Agent: Zealand Pharma A/s

20130053345 - Bicyclic heteroarly analogues as gpr119 modulators: Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R2 and R4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or... Agent: Bristol-myers Squibb Company

20130053347 - Pro-drugs of amaryllidaceae isocarbostyril products and their use against brain tumors: The present invention relates to the biology and mechanism of action of the naturally occurring compound Narciclasine, especially as an anti-cancer agent for brain tumors. The invention provides new insights on the target molecule of Amaryllidaceae isocarbostyril derivatives as for example Narciclasine and provides new prodrugs of these Amaryllidceae isocabostyril... Agent: Universite Libre De Bruxelles

20130053346 - Pyrimido-pyridazinone compounds and methods of use thereof: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2... Agent: Endo Pharmaceuticals Inc

20130053348 - Certain chemical entities, compositions, and methods: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.... Agent:

20130053349 - Biocide compositions comprising alkoxylated oligoglycerol esters: Suggested are biocide compositions, comprising (a) Alkoxylated oligoglycerol esters; (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show excellent adjuvant properties.... Agent: CognisIPManagement Gmbh

20130053350 - Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases: The present invention relates to thiazolidinedione analogues and pharmaceutical compositions that are useful for treating and/or preventing neurodegenerative disorders.... Agent: Metabolic Solutions Development Company, LLC

20130053351 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.... Agent: Bionomics Limited

20130053352 - Diazeniumdiolate cyclopentyl derivatives: A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, —OH, —O—C1-6 alkyl, ═O, or halogen; R2 is hydrogen, C(O)OR8, C6H5C(O)OR8, (CH2)1-2OH, CR9R10OH, C(O)O(CH2)0-2 aryl, C(O)NR9R10, C(O)SO2NR9R10, C6H5OR9, W—C(O)OR8, W—OR9, Y, or P(O)(OR9)(ORlO); R3 is hydrogen or —C1-6 alkyl; R4 is hydrogen, —OH or —C(O)OR9;... Agent: Merck Sharp & Dohme Corp.

20130053353 - Compositions, gels and foams with rheology modulators and uses: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.... Agent: Foamix Ltd.

20130053354 - Bone-transplant or bone-filling composition comprising a dihydroxybenzoic acid derivative: Provided is a bone-transplant or bone-filling composition, which comprises a dihydroxybenzoic acid derivative which has been newly demonstrated to increase the activity of osteoblasts and so induce bone formation.... Agent:

20130053356 - 2-methylene-19,23,24-trinor-1alpha-hydroxyvitamin d3: Compounds of Formula I are provided where R1 and R2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent:

20130053355 - Products for anti-inflammation support: This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.... Agent: Rock Creek Pharmaceuticals, Inc.

20130053359 - New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities: The present disclosure relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.... Agent:

20130053357 - Skin irritation suppressant and transdermal preparation: Provided is a skin irritation suppressant for transdermal preparations, having a sufficient reduction effect of skin irritation due to a drug. Also provided is a transdermal preparation comprising the skin irritation suppressant. One embodiment of the invention is a skin irritation suppressant for suppressing the skin irritation due to a... Agent: Hisamitsu Pharmaceutical Co., Inc.

20130053358 - Transdermally absorbable donepezil-containing preparation: Provided is a transdermal preparation having low skin irritation as well as a sufficient skin permeability rate of donepezil, which comprises one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof. Also provided are a manufacturing method thereof, and a method for reducing skin irritation of a transdermally... Agent: Hisamitsu Pharmaceutical Co., Inc.

20130053360 - Controlled release and taste masking oral pharmaceutical composition: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution... Agent: Cosmo Technologies Limited

20130053362 - Heterocyclic compounds and uses thereof: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.... Agent: Infinity Pharmaceuticals, Inc.

20130053363 - Imidazo[1,2-a]pyridine derivative: The present inventors examined compounds having PDE4B inhibitory activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had a superior PDE4B inhibitory activity, thereby completing the present invention. The imidazo[1,2-a]pyridine derivative can be used as an agent for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression... Agent: Astellas Pharma Inc.

20130053361 - Therapeutic isoxazole compounds: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are... Agent:

20130053364 - Sulphone compounds and methods of making and using same: The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.... Agent:

20130053365 - Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp): e

20130053366 - Compounds and methods for treatment of hypertension: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii)... Agent:

20130053367 - Compounds and methods of treating diabetes: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2B and the compounds are... Agent:

20130053368 - Methods for treatment of parkinson's disease: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or... Agent: Newron Pharmaceuticals S.p.a

20130053369 - Tetrahydrobenzothiophene compound: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form... Agent: Astellas Pharma Inc.

20130053372 - 5-ht receptor modulators: The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.... Agent: Cambridge Enterprise Limited

20130053371 - Inhibitors of pi3 kinase: There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a... Agent: Centro Nacional De Investigaciones Oncol&#xd3 Gicas (cnio)

20130053370 - Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.... Agent: Korea Institute Of Science And Technology

20130053373 - Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds: e

20130053374 - Ophthalmic composition: The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such... Agent:

20130053375 - Amino-quinolines as kinase inhibitors: e

20130053376 - Novel tyrosine kinase inhibitors: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.... Agent:

20130053377 - Inhibitors of beta-secretase: The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.... Agent: Vitae Pharmaceuticals, Inc.

20130053378 - Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular,... Agent: Erimos Pharmaceuticals LLC

20130053379 - 4-aryl-2-anilino-pyrimidines: The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in... Agent: Janssen Pharmaceutica Nv

20130053380 - Novel compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune disease: The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable... Agent: Phenex Pharmaceuticals Ag

20130053381 - 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives: The invention relates to a 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivative being (A) a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; or (B) a compound selected from a certain group of 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivatives disclosed in the specification; in free... Agent: Novartis Ag

20130053383 - Indazoles: e

20130053382 - Inhibitors of phosphoinositide dependent kinase 1 (pdk1): The instant invention provides for compounds that inhibit PDK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting PDK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent:

20130053384 - Certain chemical entities, compositions, and methods: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.... Agent: Neupharma, Inc.

20130053385 - Method of combating and controlling pests: e

20130053386 - Diaryl ether derivatives as notch sparing gamma secretase inhibitors: The invention encompasses a novel class of diaryl ether derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods... Agent:

20130053387 - Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents: Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of... Agent: Ferrokin Bioscience, Inc.

20130053390 - 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives: The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxaline-piperazine compounds are also included.... Agent: Korea Research Institute Of Chemical Technology

20130053389 - Certain chemical entities, compositions and methods: Provided is a method of treating myasthenia gravis in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator, or a pharmaceutically acceptable salt thereof.... Agent:

20130053388 - Pyrazolopyrazine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20130053391 - Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin: T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in... Agent: Sloan-kettering Institute For Cancer Research

20130053392 - Carbonic anhydrase inhibitors: A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R—NH—CX—NH—(CH2)n—Ar-Q-SO2—NH2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n=0, 1 or 2; Q is O or NH; X is O or S; and R comprises an organic substituent group.... Agent:

20130053393 - Methods and compositions for treating peripheral vascular disease: The invention features a method of treating a peripheral vascular disease or a condition associated with a peripheral vascular disease by administering to a subject an effective amount of at least one phosphodiesterase type 5 inhibitor and at least one nitric oxide donor. The invention also features compositions formulated for... Agent: Exodos Life Sciences Limited Partnership

20130053394 - Pyrazolopyrimidine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20130053395 - Pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20130053396 - Piperidine and piperazine derivatives as smo antagonists: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for... Agent:

20130053397 - Indoles: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful in treating cancer.... Agent:

20130053398 - Modulators of fatty acid amide hydrolase: 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy... Agent: Janssen Pharmaceutica Nv

20130053399 - Methods of administering antihistamines: Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed.... Agent:

20130053400 - Oligomer-antihistamine conjugates: The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20130053403 - Novel beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.... Agent:

20130053402 - Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals: wherein G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for... Agent: Sanofi

20130053401 - Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.... Agent:

20130053404 - Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation: e

20130053405 - Carrier linked paliperidone prodrugs:

20130053406 - Therapeutic compounds and uses thereof: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders such as cancer.... Agent: Myrexis, Inc.

20130053407 - Pyrrolo [3,2-d] pyrimidin-3-yl derivatives used as activators of ampk: Pyrrolopyrimidones compounds of the formula (I), salts thereof, and pharmaceutical compositions containing them are disclosed herein, as well as methods for their use in medicine, for instance as activators of AMPK.... Agent: Glaxosmithkline LLC

20130053408 - Methods and compositions utilizing quinazolinones: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.... Agent:

20130053409 - 2-(2,4,5-substituted-anilino) pyrimidine compounds: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and... Agent: Astrazeneca Ab

20130053410 - Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione: e

20130053411 - Pharmaceutical composition and method for treating hypertension: Dextromethorphan is used to lower blood pressure in a subject suffering from hypertension, alone or in combination with another anti-hypertensive agent. In particular, dextromethorphan acts synergistically with a calcium channel blocker, such as amlodipine, to result in a major improvement in the treatment of hypertension, with no or little adverse... Agent: Tsh Biopharm Corporation Ltd.

20130053412 - Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use: The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R1, R2, R3, LO, W, AR1, n are as defined in claim 1.... Agent: Boehringer Ingelheim International Gmbh

20130053413 - Crystalline forms of pitavastatin calcium: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous... Agent: Nissan Chemical Industries, Ltd.

20130053414 - Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including... Agent:

20130053415 - Combination methods for treatment of disease: In some aspects, the invention provides compositions and methods of use for treating a variety of diseases. In some aspect, the compositions and methods involve combined modulation of transcriptional modulators.... Agent:

20130053416 - 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals: wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases,... Agent: Sanofi

20130053417 - Cetp activity inhibitors: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity, the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.... Agent: Japan Tobacco Inc.

20130053418 - Acyclic organonitro compounds for use in treating cancer: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.... Agent:

20130053419 - Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors: Compounds which are sulfonamido 3,4-diarylpyrazole derivatives, or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in... Agent:

20130053420 - Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions: Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.... Agent:

20130053421 - Method for flying insect control: The present invention relates to a flying insect trap insecticidal insert which is coated on at least one side with a composition comprising a neonicotinoid insecticide and a food attractant.... Agent: Fmc Corporation

20130053422 - Antimicrobial compositions: Environmentally beneficial antimicrobial compositions are described that include a cationic surfactant and certain antimicrobial agents or preservatives. Useful cationic surfactants include lauric arginate (LAE). Advantageously, the pH of the composition may be adjusted to reduce irritancy.... Agent:

20130053423 - Cosmetic use of substituted amino heterocylic carbamoyl analogs and related compounds: Cosmetic compositions comprising substituted amino heterocyclic carbamoyl analogs and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The substituted amino heterocyclic carbamoyl analogs are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging.... Agent: Avon Products, Inc.

20130053424 - Plant disease control composition and its use: A composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and one or more acylalanine compounds selected from group (A) consisting of methyl N-(methoxyacetyl)-N-(2,6-xylyl)alaninate and methyl... Agent: Sumitomo Chemical Company, Limited

20130053425 - Method for lowering intraocular pressure using gap junction blockers: A pharmaceutical composition contains a gap junction blocker, and a pharmaceutically acceptable carrier. In addition, a pharmaceutical composition contains a gap junction blocker, a pharmaceutically acceptable carrier, a preservative and a buffer. Also, a method of lowering intraocular pressure includes the step of administrating to a subject a pharmaceutical composition... Agent:

20130053433 - Fatty acid derivatives and analogs of drugs: The present disclosure is directed to fatty acid-drug conjugates, the preparation and use thereof and long-chain (C10-25), both saturated and unsaturated, fatty acids and anhydrides useful for preparing drug conjugates.... Agent: The University Of North Carolina At Chapel Hill

20130053434 - Irreversible inhibitors useful for the treatment of kinase-related pathologies: The present invention provides new compounds having a kinase inhibitory activity and useful for treating cancer.... Agent: Universite De Strasbourg

20130053436 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent:

20130053435 - Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprises the administration of dihydromyricetin: Disclosed herein are methods for treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin. As disclosed herein, dihydromyricetin potentiates the activity of GABAARs having the alpha4-beta-delta subunit which is associated with the effects of ethanol, antagonizes the actions of ethanol on the GABAARs, acts... Agent:

20130053437 - Anti-inflammatory compounds: New clerodane compounds isolated from plant material from Dodonaea polyandra are disclosed. The compounds have anti-inflammatory activity. Pharmaceutical and cosmetic compositions containing the compounds, as well as methods of treating inflammation using the compounds, are also disclosed.... Agent: University Of South Australia

20130053438 - Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity: The present invention relates to a pharmaceutical composition for stimulating angiogenesis and/or the treatment or prevention of hypovascularity and/or the prevention and/or treatment of an angiogenic disorder/disease, whereby the composition comprises specific compounds which may be obtained from Leontopodium alpinum Cass, (Edelweiss). These compounds relate to lignan compounds as shown... Agent: Medizinische Universitat Wien

20130053439 - Disinfectant composition: The invention relates to a disinfectant composition (i) comprising a combination of citric acid or a physiologically acceptable salt thereof as component (A), and poly(hexamethylene-biguanide) (PHMB) or a physiologically acceptable salt thereof as component (B) and/or (ii) exhibiting a log reduction of staphylococcus aureus of at least 4.0 after a... Agent:

20130053440 - Self-preserved aqueous pharmaceutical compositions: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions... Agent: Alcon Research, Ltd.

20130053441 - Novel ester derivative and use thereof: Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X1 is a methylene group, then... Agent: Ajinomoto Co., Inc.

20130053442 - Balanced myristate- and laurate-containing edible oil: Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition... Agent: Brandeis University

20130053443 - Method for preparing extract containing omega fatty acids from plant by using supercritical carbon dioxide extraction: The present invention relates to a method for preparing an extract containing omega fatty acids from a plant containing omega fatty acids, including the following steps: drying the plant containing omega fatty acids to prepare a powder; and extracting omega fatty acids from the prepared plant powder by using supercritical... Agent: Mnf Korea Co., Ltd.

20130053444 - Dp2 antagonist and uses thereof: Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 anatgonist, or a pharmaceutically acceptable... Agent: Panmira Pharmaceuticals, LLC

20130053445 - Levothyroxine formulations: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine... Agent: Fresenius Kabi Usa, LLC

20130053446 - Pharmaceutical preparations having individualized dosage and structure: A manufacturing device capable of creating individualized dosages of pharmaceutical preparations in which a metering system and a means of performing non-destructive chemical analysis of individual manufactured units are controlled by a microprocessor to precisely control the content and structure of each individual unit.... Agent: Rutgers, The State University Of New Jersey

20130053447 - Desensitizing drug product: Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents.... Agent: Absorption Pharmaceuticals, LLC

20130053448 - Therapeutic regimens: This invention relates to clinically useful therapeutic regimens comprising the administration of (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol.... Agent:

20130053449 - Method for inhibiting histone gene transcription and expression: A method for inhibiting at least one of histone gene transcription and histone expression in a subject is provided. The method comprises administrating to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:... Agent: China Medical University

20130053450 - Treatment of pervasive developmental disorders with redox-active therapeutics: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.... Agent: Edison Pharmaceuticals, Inc.

20130053451 - Biocide compositions (i): Suggested are biocide compositions, comprising (a) at least one dialkylamide based on a hydroxycarboxylic acid, and (b) at least one biocide. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. over a longer period.... Agent: CognisIPManagement Gmbh

20130053452 - Composition made of polyalkoxylated derivatives of trimethylolpropane and fatty alcohols, method for preparing said composition, and use thereof as a reverser in self-reversible reverse latexes: A novel composition made of polyalkoxylated derivatives of trimethylolpropane and fatty alcohols, the composition lending itself to the preparation thereof and to the use thereof as a reversing agent for a reversible reverse latex.... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20130053453 - Dermal filler composition: The present invention relates to a novel dermal filler composition and a method for preparing the same. Even though the composition of the present invention comprises, as a main component, only cross-linked dextran having the molecular weight of 30,000 to 100,000, the composition can rapidly augment a detective area of... Agent:

20130053454 - Process for the production of a composition comprising fibrillated cellulose and a composition: The present invention relates to a process for the production of a composition wherein the process comprises pre-treating cellulosic fibers by mechanical, chemical and/or enzymatic treatment, mixing the pre-treated cellulosic fibers with pigments forming a dispersion and dispersing the dispersion of pre-treated cellulosic fibers and pigments whereby a composition comprising... Agent: Stora Enso Oyj

20130045914 - Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators: In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment,... Agent: Merck Sharp & Dohme Corp

20130045915 - Method for weight loss and ketogenic compositions: The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition induces body weight loss when administered to a subject as the only source of nutrition for at least 12 hours.... Agent: European Ketogenic Weight Loss Clinics LLC

20130045916 - Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20130045917 - Method of selecting polypeptide sequence, and metal oxide or silicon-containing compound binding peptide and use thereof: Provided is a peptide including the following amino acid sequence. Tyr-Xaa0-Xaa1-Tyr-Tyr-Xaa2-Xaa3-Tyr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 (SEQ ID NO: 4: wherein Xaa0, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10 and Xaa11 represent any amino acid) or Tyr-Asn-Asp-Tyr-Tyr-Tyr-Tyr-Cys-Tyr-Arg-Asp-Tyr-Asp (SEQ ID NO: 20).... Agent: Riken

20130045918 - Methods for treating diabetic wounds: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.... Agent: New York University

20130045920 - Flowable ceramic putty: The invention relates to a composition comprising an aqueous admixture of ceramic particles, polysaccharide, a therapeutic agent and, optionally, a polymer, and methods of using the same. The present invention provides a flowable bone void filler for use in medical situations where bone regeneration is desired. In an exemplary embodiment... Agent: Warsaw Orthopedic, Inc.

20130045919 - Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents: The present invention is directed to sustained release formulations of biologic agents which permit persistent bioavailability. Preferred biologic agents include bone morphogenetic proteins. Diseases susceptible to amelioration and/or treatment with the formulations of the present invention include skeletal tissue diseases such as, but not limited to, osteoarthritis and other osteochondral... Agent:

20130045921 - Therapeutic agent for rhinitis: e

20130045922 - Pro-angiogenic fragments of prominin-1 and uses thereof: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these... Agent: Children's Medical Center Corporation

20130045923 - Collagenous material: The present invention relates to a collagenous material and to a process for the manufacture thereof. The process is for the manufacture of a collagenous material from a plurality of collagen particles, wherein said collagen particles are derived from a natural tissue material and are substantially free of non-fibrous tissue... Agent: Tissue Science Laboratories PLC

20130045924 - Methods of reducing hypoxic stress in a mammal by administering soluble p-selectin: The present invention provides a use of soluble P-selectin in treating systemic hemorrhagic conditions, stabilizing blood pressure, and protecting hypoxic/ischemic tissues. Also provided is a use of anthrax lethal toxin in treating thrombotic conditions.... Agent:

20130045925 - Compositions for ameliorating cell proliferative disorders and methods of making and using them: In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. 1) and apratoxin G (compound 7 of... Agent: The Regents Of The University Of California

20130045926 - Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema: Methods of stabilizing and organizing collagen fibrils in extracellular matrix of retinal tissues, particularly Bruch's membranes, and stabilizing retinal pigment epithelial layers lining Bruch's membrane are disclosed. The stabilization and organization may be effected by treating retinal tissues with a protein that crosslinks and organizes collagen fibrils, such as decorin.... Agent:

20130045927 - Therapeutic compositions for the treatment of dry eye disease: Described herein are materials and methods of treating dry eye disease in a subject.... Agent: Schepense Eye Research Institute

20130045928 - Uses of natriuretic peptide constructs: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or COPD, methods of prophylaxis and treatment of... Agent: Palatin Technologies, Inc.

20130045929 - Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of... Agent: Apotex Technologies Inc.

20130045930 - Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 2 (polymorphic form I) of the mono-sodium salt of... Agent: Apotex Technologies Inc.

20130045931 - Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes: The invention relates to a compound of the general structure (I), where R is a hydrogen atom (H) or an unsubstituted, monosubstituted, or polysubstituted C1-C20 alkyl, wherein the alkyl can be straight, branched, cyclic, or partially unsaturated, or an unsubstituted, monosubstituted, or polysubstituted phenyl group.... Agent: Geomar Helmotz-zentrum F&#xfc R Ozeanforschung Kiel

20130045932 - Retinoid topical compositions and methods for treating skin conditions: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.... Agent: Allergan, Inc.

20130045933 - Aloe-emodin derivatives and use thereof for the treatment of cancer: The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageously, these derivatives are potent cytotoxic agents against a variety of anthracycline-resistant tumors. In addition, they may have... Agent: Ramot At Tel-aviv University Ltd.

20130045934 - Extraction method using ultra fine bubbles and liquid extracts obtained thereof: The present invention provides an extraction method that either does not use emulsifiers, organic solvents, and the like or can reduce the amount used of emulsifiers, organic solvents, and the like. In addition, the extraction method of present invention can also efficiently extract various components from various materials to be... Agent: Ligaric Co., Ltd.

20130045935 - Flavonoid dimers and their use: e

20130045936 - Composition comprising an amorphous non-crystalline glass form of roxithromycin: The invention relates to an amorphous non-crystalline glass form (Form-ll) of 3R,4S,5S,6R,7R,9R,11S,12R,13S,14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxa-cyclotetradecan-2-one or roxithromycin having at least one characteristic infra-red spectrum peak at approximately 3580 to 3464 cm−1. The invention further relates to a preparation method of increasing the solubility of roxithromycin including the steps of selecting anhydrous roxithromycin or... Agent: North-west University

20130045939 - Fatty acid macrolide derivatives and their uses: The invention relates to fatty and macrolide derivatives; compositions comprising an effective amount of fatty acid macrolide derivative; and methods for treating or preventing an autoimmune disorders and diseases with inflammation as the underlying etiology comprising the administration of an effective amount of a fatty acid macrolide derivative.... Agent: Catabasis Pharmaceuticals, Inc.

20130045938 - Kinase modulators for the treatment of cancer: A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in... Agent: Synovo Gmbh

20130045937 - Parenteral formulations of macrolide antibiotics: Described herein are pharmaceutical compositions adapted for the parenteral administration of macrolide antibiotics, such as triazole-containing and fluoroketolide antibiotics. Also described herein are methods for their use in the treatment of bacterial, protozoal, and other infections.... Agent: Cempra Pharmaceuticals, Inc.

20130045940 - Composition comprising as active ingredient l-carnitine in combination with a solar filter, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation: It is described a composition in the form of eye drops or ointment, comprising as active ingredients L-carnitine or a physiologically acceptable salt thereof; and 3-Hydroxykynurenine O-β-DL-glucoside, useful for preventing or treating pathologies of the eyes due to ultraviolet radiation.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20130045941 - Dimethyl sulfoxide (dmso) or dmso and methylsulfonylmethane (msm) formulations to treat infectious diseases: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.... Agent: Abela Pharmaceuticals, Inc.

20130046006 - Inhibitors of fam3b gene, inhibitor compositions, inhibiting methods and applications of inhibitors in preparing pharmaceuticals: Inhibitors that can inhibit expression of FAM3B gene to reduce the levels of expression products, or can combine the expression products to reduce the activity of promoting lipid synthesis of FAM3B gene product are provided, wherein the inhibitors are one or more inhibitors selected from the group consisting of small... Agent: Suzhou Ribo Life Science Co., Ltd.

20130046009 - Rho kinase inhibitors for treatment of mastocytosis and acute myeloid leukemia: The disclosure is directed to methods of treating hematologic malignancies. More particularly, the disclosure is directed to methods of treating hematologic malignancies using Rho kinase (ROCK) inhibitors and myosin light chain-specific inhibitory RNA molecules. The disclosure is further directed to methods of identifying drug candidates for inhibiting ROCK in hematologic... Agent:

20130046007 - Selective reduction of allelic variants: Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).... Agent: Isis Pharmaceuticals Inc.

20130046008 - Selective reduction of allelic variants: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).... Agent: Isis Pharmaceuticals, Inc.

20130046010 - Sumo as a marker of cancer development and target for cancer therapy: Disclosed herein are methods relating to inhibiting or reducing proliferation of a cancer cell, for treating cancer in a subject in need of treatment, predicting the risk of progression of cancer to a more aggressive cancer, and screening for cancer in a subject, that comprise detecting and/or decreasing the levels... Agent: Duke University

20130045943 - A3ar agonists for the treatment of uveitis: The present disclosure relates to the use of an A3AR agonist, such as IB-MECA, for the treatment or prevention of uveitis in a subject, as well as to methods for such treatment and pharmaceutical compositions comprising an amount of IB-MECA effective to treat uveitis.... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department Of

20130045942 - N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.... Agent: Institute Of Materia Medica, Chinese Academy Of Medical Sciences

20130045944 - Anti-cancer therapies: Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.... Agent: Threshold Pharmaceuticals, Inc.

20130045945 - Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently... Agent: Anika Therapeutics, Inc.

20130045946 - Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved: The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes,... Agent:

20130045947 - Pla2activity as a marker for ovarian and other gynecologic cancers: Materials and Methods are provided for the diagnosis, monitoring, and personalized treatments of gynecological cancers. The methods comprise determining levels of PLA2 activity in sample of tissue or fluid recovered from patient; elevated levels of PLA2 activity are consistent with epithelial ovarian cancer (EOC). These methods include assaying for PLA2... Agent: Indiana University Research And Technology Corporation

20130045948 - Azocyclic inhibitors of fatty acid amide hydrolase: t

20130045949 - Anti-cancer agents: Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.... Agent: Uwm Research Foundation, Inc.

20130045950 - Phosphonate compounds: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.... Agent: The Regents Of The University Of California

20130045951 - Novel nitroso compounds as nitroxyl donors and methods of use thereof: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl... Agent: Cardioxyl Pharmaceuticals, Inc.

20130045952 - Aba receptor agonists for increased plant stress resistance: The present invention relates to ABA agonist compounds which increase plant stress resistance. The invention also relates to methods of using these compounds. The invention further relates to compositions and formulations comprising the ABA agonist compounds, and uses thereof.... Agent: Van Andel Research Institute

20130045953 - Nestorone®/estradiol transdermal gel: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions... Agent: The Population Council, Inc.

20130045954 - Antimicrobial composition: Antimicrobial compositions comprising a terpenoid in combination with an antimicrobial agent are provided. In addition, uses of such compositions in various applications involving preventing, combating or treating microbial infections, or preventing microbial growth or establishment are provided.... Agent: University Of Surrey

20130045955 - Novel compounds: t

20130045956 - Preventive and/or therapeutic agent of hand-foot syndrome: The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior... Agent:

20130045958 - Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.... Agent: Trimel Pharmaceuticals Corporation

20130045957 - Prevention of and recovery from drug-induced ototoxicity: Provided herein are methods for preventing and/or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.... Agent: Otonomy, Inc.

20130045959 - Method for late post coital contraception using ulipristal acetate: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotected intercourse.... Agent:

20130045960 - Abuse-deterrent pharmaceutical compositions of opiods and other drugs: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is... Agent: Collegium Pharmaceuticals, Inc.

20130045961 - Personal care compositions having dried zinc pyrithione: Personal care compositions including dried zinc pyrithione are provided. Methods are also provided to increase antimicrobial efficacy and enhance deposition of zinc pyrithione... Agent:

20130045963 - Cyclohexyl azetidine derivatives as jak inhibitors: The present invention provides cyclohexyl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.... Agent: Incyte Corporation

20130045964 - Mandelamide heterocyclic compounds: Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled... Agent:

20130045962 - Peptide deformylase inhibitors: s

20130045965 - Inhibitors of bruton's tyrosine kinase: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such... Agent:

20130045966 - Method of lowering serum uric acid levels with (s)-tofisopam: Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.... Agent: Pharmos Corporation

20130045967 - Compounds for modulating integrin cdiib/cdi8: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening... Agent:

20130045970 - Pesticidal composition and its use: A composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifiuoromethyl group, and one or more neonicotinoid compound selected from group (A) consisting of acetamiprid, clothianidin, dinotefuran, imidacloprid,... Agent: Sumitomo Chemical Company, Limited

20130045969 - Plant disease controlling composition and method for controlling plant disease: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more strobilurin fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting... Agent: Sumitomo Chemical Company, Limited

20130045968 - Plant treatment: An anti-fungal treatment for trees and bushes. Included are all methods of delivery of active ingredients, including foliar and trunk spraying application, granular soil surface, soil drench, soil injection, and trunk injection. The chemical combination includes a group 3 fungicide like propiconazole, that is, a systemic with curative and protective... Agent:

20130045971 - Induced hypothermia: Sudden cardiac arrest is treated by reducing blood temperature from about 37° C. to 33° C., following resuscitation, by injecting hypothermia inducing drugs such as a cannabinoid type into the patient's body, preferably in combination with physical surface body cooling.... Agent:

20130045973 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: d

20130045972 - Glucocorticoid receptor antagonists:

20130045974 - Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors:

20130045975 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Kalypsys, Inc.

20130045976 - Isoindoline compounds and methods of their use: Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.... Agent: Celgene Corporation

20130045977 - Tgf-beta signal transduction inhibitor: o

20130045978 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.... Agent:

20130045979 - Method of treating major depressive disorder: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to... Agent: Lcs Group, LLC

20130045980 - Imidazopyridazinyl compounds: Disclosed are imidazopyridazinyl compounds of Formula (I): (I), or pharmaceutically salts and prodrugs thereof, wherein R3 is C2-4alkenyl or a cyclic group, and R1 and R2 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for... Agent: Bristol-myers Squibb Company

20130045981 - Aripiprazole complex formulation and method: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or... Agent: Bristol-myers Squibb Company

20130045982 - Benzamide derivatives: Disclosed are benzamide derivatives useful in slowing the expansion of cancer cells including the killing of cancer cells and in the treatment of cancer.... Agent: The Translational Genomics Research Institute

20130045983 - Hsp90 inhibitors for therapeutic treatment: The use of a Hsp90 inhibitor for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain,... Agent: Novartis Ag

20130045984 - 5-fluoro-4-imino-3,4-dihydropyrimidin-2-(1h)-ones derivatives: This present disclosure is related to the field of 5-fluoro-4-imino-3-(substituted)-3,4-dihydropyrimidin-2(1H)ones and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20130045985 - N-(5-fluoro-2-((4-methylbenzyl)oxy)pyrimidin-4-yl)benzamide derivatives: This present disclosure is related to the field of N-(5-fluoro-2-((4-methylbenzyl)oxy)pyrimidin-4-yl)benzamides and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20130045986 - Novel compounds as modulators of gpr-119: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.... Agent: Rhizen Pharmaceuticals Sa

20130045987 - Novel methods of use of tetrahydroberberine (thb): Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional... Agent: Dignity Health

20130045988 - Combination therapy: Described herein is a combination comprising at least one 5-HT4 receptor agonist and at least one phosphodiesterase 4 (PDE4) inhibitor, and methods and uses thereof in the prevention and/or treatment of one or more disorders in which an increased acetylcholine release is desired; for example in the prevention and/or treatment... Agent: Shire Ag

20130045989 - Stabilized crystal of 2-ethyl-3,7-dimethyl-6-(4-(trifluoromethoxy)phenoxy)quinoline-4-yl methyl carbonate, process for producing the crystal, and agricultural chemical composition comprising the crystal: s

20130045990 - Novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes:

20130045991 - Neuroprotective modulation of nmda receptor subtype activities: In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity... Agent: The University Of British Columbia

20130045992 - Compositions and methods for enhancing proteasome activity: Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp 14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of... Agent: President And Fellows Of Harvard College

20130045993 - Inhibitors of cyclin-dependent kinases and their use: wherein R1, R2, R3, R4, R5, R6, R7, and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of... Agent:

20130045994 - Pyridine derivative: [wherein R represents a pyridyl group substituted with 1 to 3 group(s) independently selected from Substituent Group A, and Substituent Group A represents a halogen atom, a C1-C6 alkyl group and a C1-C6 alkoxy group] or a pharmacologically acceptable ester thereof, or a pharmacologically acceptable salt of the compound or... Agent: Daiichi Sankyo Company, Limited

20130045995 - Fungicide hydroximoyl-heterocycles derivatives: h

20130045996 - Combination product for controlling parasites on animals: The invention relates to novel compositions for controlling parasites on animals, comprising an N-arylpyrazole and also a pyrethroid in a formulation comprising aliphatic cyclic carbonates and aliphatic cyclic or acyclic polyethers.... Agent: Bayer Animal Health Gmbh

20130045997 - Pirfenidone therapy and inducers of of cytochrome p450: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.... Agent: Intermune, Inc

20130045998 - Process for preparing rufinamide intermediate: The present invention refers to an improved method for the preparation of compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid substantially free of its 3H-I isomer. The invention also refers to the use of said intermediate for the preparation of Rufinamide and for obtaining a new polymorphic form of Rufinamide, designed as Form R-5. The... Agent: Laboratorios Lesvi, S.l.

20130045999 - Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof: The present invention relates to novel substituted furancarboxamides, methods for their production, their use for the treatment and/or prevention of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially retroviral diseases, in humans and/or animals.... Agent: Aicuris Gmbh & Co. Kg

20130046000 - Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.... Agent: Takeda Pharmaceutical Company Limited

20130046001 - Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration: Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.... Agent: Sk Biopharmaceuticals Co., Ltd.

20130046002 - Triazole compound having pesticidal activities: To provide a triazole compound which has remarkably excellent pesticidal activities. Optically active (+)-1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-(trifluoromethyl)-1H-1,2,4-triazole represented by the following formula (I), which is obtainable by subjecting a racemic modification of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-(trifluoromethyl)-1H-1,2,4-triazole to optical resolution:... Agent: Kumai Chemical Industry Co., Ltd.

20130046003 - Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases: The present invention relates to a method for treating retinal diseases and a method for retinal neuroprotection, in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or pharmaceutically acceptable salts thereof.... Agent:

20130046004 - Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases... Agent: Sanofi

20130046005 - Treatment of immune disorders using kainate receptor antagonists: Allergies and immune system disorders (e.g. autoimmune diseases) are treated by administration of an agent that blocks activation of the kainic acid receptor (KAR) in B cells. The agents include antagonists and weakly activating agonists.... Agent:

20130046011 - Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof: A hot-melt extruded composition is disclosed that includes about 20-80% wt. of a plant-derived phenolic material; about 20-85% wt. of one or more edible or bioerodible excipients; about 0-40% wt. of a surface active material; about 0-40% wt. of an oral absorption enhancer; and about 0-10% wt. of one or... Agent: Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations

20130046012 - New compounds, synthesis and use thereof in the treatment of pain: h

20130046013 - Salicylate fatty acid derivatives: Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating various diseases comprising the administration of an effective amount of at least one compound according to the present disclosure.... Agent:

20130046014 - Pharmaceutical composition for treatment of increased intraocular pressure: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides... Agent: Novaliq Gmbh

20130046015 - Therapeutic inhibition of granulocyte function in demyelinating disease: Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment... Agent:

20130046016 - Method for lowering cholesterol: The present invention relates to a method of lowering cholesterol in a patient in need thereof by administering to said patient a therapeutic effective amount of a compound selected from the group of Dihydroxyacetone phosphate (DHAP); 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl,2-acyl-glycerylphosphatidylethanolamine (GPE), 1-alkyl, diacyl glycerol (sn-1=16:0,... Agent: Phenomenome Discoveries Inc.

20130046017 - Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them: e

20130046018 - Dietary supplements containing terpenoid acids of maslinic acid or oleanolic acid and process for enhancing muscle mass in mammals: A process for increasing lean body mass in a mammalian subject is provided that includes administering to the subject a purified quantity of maslinic acid, oleanolic acid, or a combination thereof. The administration can be orally and benefits from ingestion of an amino acid source such as dietary protein, oligopeptides,... Agent: Fhg Corporation D/b/a Integrity Nutraceuticals

20130046019 - Methods of treatment using 3-bromopyruvate and other selective inhibitors of atp production: The present invention provides methods for preventing or treating infections, especially bacterial infections, by administering selective inhibitors of ATP production to inhibit glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As such, the present invention further provides methods for preventing or treating inflammation and sepsis associated with infections, as well... Agent: Prescience Labs, LLC

20130046020 - Eicosapentaenoic acid concentrate: An omega-3 oil concentrate comprising at least 70 weight percent of eicosapentaenoic acid [“EPA”; cis-5,8,11,14,17-eicosapentaenoic acid; omega-3], measured as a weight percent of oil, and substantially free of docosahexaenoic acid, said concentrate obtained from a microbial oil having 30 to 70 weight percent of eicosapentaenoic acid, measured as a weight... Agent: E I Du Pont De Nemours And Company

20130046021 - Methods of treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure with probenecid: Described herein are inventions is directed to methods of treating a cardiac dysfunction and symptoms of cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or... Agent: University Of Cincinnati

20130046022 - Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected... Agent: Galderma Research & Development

20130046023 - Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses: A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.... Agent: Snu R&db Foundation

20130046024 - Composition, method and kit for enhancing hair: p

20130046025 - Composition with low skin irritation for transdermal delivery of tolterodine: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises at least one essential oil as an abirritant to minimize skin irritation caused by tolterodine. The composition relieves skin irritation caused by tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can... Agent: Sk Chemicals Co., Ltd.

20130046026 - Composition with improved skin penetration for transdermal delivery of tolterodine: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.... Agent: Sk Chemicals Co., Ltd.

20130046027 - Chocolate with agglomerate structure and the method for preparing thereof: The present invention relates to a method for preparing chocolate with agglomerate structure. It also relates to the chocolate obtained by said method characterized in that has the organoleptic characteristics of the conventional chocolate, it is physico-chemically stable at a temperature greater than or equal to 40° C., maintains its... Agent:

20130046028 - Cosmetic raw material: A cosmetic raw material comprising the following components (A), (B), and (C): (A) a specific polyether-modified organopolysiloxane; (B) a chain-form silicone oil that is a liquid at 25° C., does not contain a cyclic structure, and does not contain a resinous structure; and (C) an oil that is a liquid... Agent: Dow Corning Corporation

20130046029 - Anti-ultraviolet additive comprising a uva filter, a uvb filter and an oil that is a solvent for said filters, and use thereof in coloured and/or perfumed compositions: The invention relates to an additive comprising at least 95 wt. % of a mixture consisting of at least one organic filter filtering UVA, at least one organic filter filtering UVB, and from 1 to 50 wt. % of at least one non-volatile oil that is a solvent for said... Agent: Lvmh Recherche

20130040876 - Method for sensitizing cells to cancer therapy: Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth... Agent: Orbis Health Solutions LLC

20130040877 - Long-acting y2 receptor agonists: The present invention relates to PYY analogues or derivatives thereof comprising at least one alteration selected from the group consisting of substitutions, insertions, deletions and modifications and optionally a serum albumin binding side chain comprising an alkyl chain with at least 14 carbon atoms. Moreover, the invention relates to compositions... Agent: Novo Nordisk A/s

20130040878 - Pharmaceutical combination for use in the treatment of diabetes type 2 patients: The present invention refers to a pharmaceutical combination for use in the treatment of diabetes type 2 patients.... Agent: Sanofi-aventis Deutschland Gmbh

20130040879 - Methods for treating congestive heart failure: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.... Agent: Acorda Therapeutics, Inc.

20130040880 - Novel cytokine containing compositions: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.... Agent: Stemnion, Inc.

20130040881 - Ltbp2 as a biomarker for renal dysfunction: The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left... Agent: Pronota N.v.

20130040882 - Use of fibroblast growth factor fragments: A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention... Agent: Novartis Ag

20130040883 - Stable growth hormone compounds: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.... Agent: Novo Nordisk Healthcare Ag

20130040884 - Albumin-binding conjugates comprising fatty-acid and peg: Novel polypeptide derivatives having protracted profile of action.... Agent: Novo Nordisk A/s

20130040885 - Collagen pad: The present invention relates to a collagen pad and to processes for the manufacture thereof. One aspect of the invention provides a process for the manufacture of a collagen pad from a plurality of collagen particles, said process comprising steps of forming a dispersion of the collagen particles in an... Agent: Tissue Science Laboratories PLC

20130040887 - Inhibiting collagen-induced platelet aggregation and activation with peptide variants: The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino... Agent: University Of Massachusetts

20130040886 - Peptides and methods for inhibiting g alpha protein signaling: The present invention comprises peptide compositions and methods for specifically inhibiting signaling through Gα subunits.... Agent: The Board Of Trustees Of The University Of Illinois

20130040889 - Factor viii fusion protein: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.... Agent: Novo Nordisk A/s

20130040888 - Factor viii molecules with reduced vwf binding: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.... Agent: Novo Nordisk A/s

20130040890 - Lyophilization methods, compositions, and kits: Method for lyophilization is provided, in particular methods for lyophilization of formulations comprising AT III. Also provided are compositions prepared by therefrom. Also provided are kits comprising the compositions and/or lyophilized products.... Agent:

20130040891 - Chemically modified water-soluble elastin, mixed gel of chemically modified water-soluble elastin and collagen, and process for producing same: A chemically modified water-soluble elastin/collagen mixed gel obtained by mixing a collagen with a chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight water-soluble elastin and coupling some or... Agent: Kyushu Institute Of Technology

20130040892 - Iap bir domain binding compounds: A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.... Agent: Pharmascience Inc.

20130040893 - Treatment of proliferative disorders: Inhibitors of cIAP-1 and methods and compositions for treating proliferative disorders.... Agent: Tetralogic Pharmaceuticals Corporation

20130040894 - Inhibition or activation of serine/threonine ulk3 kinase activity: The present invention relates to human serine/threonine kinase ULK3 and its ability to regulate GLI transcription factors; mediators of SHH signaling. This disclosure demonstrates that ULK3 enhances endogenous and over-expressed GLI1 and GLI2 transcriptional activity in cultured cells, and ULK3 alters subcellular localization of GLI1. According to this disclosure ULK3... Agent: Tallinn University Of Technology

20130040895 - Pharmaceutical formulations and methods for treating ocular conditions: Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit.... Agent: Allergan, Inc

20130040896 - Methods and compositions for modulating angiogenesis and pericyte composition: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may... Agent: Acceleron Pharma, Inc.

20130040897 - Glycosylation of proteins in host cells: The invention provides means and methods for an improved production of glycosylated recombinant proteins in lower eukaryotes, specifically the production of human-like complex or hybrid glycosylated proteins in yeast. The invention provides genetically modified eukaryotic host cells capable of producing glycosylation optimized proteins useful as immunoglobulins and other therapeutic proteins,... Agent: Lonza Ltd.

20130040898 - Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof: The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients... Agent:

20130040899 - Use of pedf-derived polypeptides for treating liver cirrhosis: The present disclosure elucidates that 34-mer PEDF suppresses hepatic stellate cells (HSCs) from activation by diminishing the levels of alpha-smooth muscle actin (α-SMC), collagen type 1, and monocyte chemoattractant protein-1 (MCP-1); and 44-mer PEDF promotes liver regeneration process by enhancing the replication of liver-derived progenitor cells (LDPCs). Accordingly, methods and... Agent: Mackay Memorial Hospital

20130040900 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.... Agent:

20130040901 - Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy: The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide.... Agent: University Of Florida Research Foundation Inc.

20130040902 - Method for enhancing milk quantity and quality: This invention provides a method for enhancing quantity and quality of milk in mammals, while improving their health. The method particularly enables to substantially increase global milk production and improve economy of the dairy industry, without negatively affecting the wellbeing of dairy cattle.... Agent: Ganir Ltd.

20130040903 - Pharmaceutical compositions for treating depression and anxiety: Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rgl+Rbl), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy.... Agent:

20130040905 - Combination of drugs with protein-binding prodrugs: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body,... Agent: Ktb Tumorforschungsgesellschaft Mbh

20130040904 - Method of treatment using alpha-1-adrenergic agonist compounds: Methods for treating or preventing cardiomyopathy in a subject by administering an α1 adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided.... Agent: The Regents Of The University Of California

20130041011 - Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom: Provided herein are novel base modified bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel pyrimidine bicyclic nucleosides are provided wherein each pyrimidine base is substituted at the 5 position with an optionally substituted, aromatic or heteroaromatic ring system comprising from 5 to... Agent: Isis Pharmaceuticals, Inc.

20130041016 - Compositions and methods for preventing and treating cancer via modulating ube1l, isg215 and/or ubp43: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also... Agent: Trustees Of Dartmouth College

20130041010 - Compositions and methods for the specific inhibition of gene expression by dsrna containing modified nucleotides: The invention features compositions and methods that are useful for reducing the expression or activity of a specified gene in eukaryotic cell.... Agent: Dicerna Pharmaceuticals, Inc.

20130041013 - Isoform of bruton's tyrosine kinase (btk) protein: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2,... Agent: Bionsil S.r.l.

20130041014 - Isoform of bruton's tyrosine kinase (btk) protein: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAl, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2,... Agent: Bionsil S.r.l.

20130041009 - Methods and means for increasing resistance to cell damage: Methods are provided to increase resistance to cell damage in a subject. The increase in resistance to cell damage in a subject in the subject is accomplished by decreasing activity of eEF2 kinase in the subject. The eEF2 kinase activity can be decreased by decreasing the amount of functional eEF2... Agent: University Of Medicine And Dentistry Of New Jersey

20130041012 - New isoform of bruton's tyrosine kinase (btk) protein: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2,... Agent: Bionsil S.r.l.

20130041017 - Sirna-based therapy of fibrodyplasia ossificans progressiva (fop): This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to compositions and methods for siRNA-based regulation of mutated ACVR1 expression in the treatment of Fibrodysplasia Ossificans Progressiva (FOP).... Agent: The Trustees Of The University Of Pennsylvania

20130041015 - Use of the lactosylceramide synthase isoform b1,4galt-v as a biomarker for cancer: In one aspect, B1,4GalT-V, an isoform of the enzyme lactosylceramide synthase, is provided as a biomarker for cancer. Also provided are methods and compositions directed at cancers characterized by the overexpression or upregulation of the lactosylceramide synthase isoform B1,4GalT-V.... Agent: The Johns Hopkins University

20130041018 - Method of treating acute myelogenous leukemia: A method of treating acute myelogenous leukemia (AML) in a subject in need thereof is carried out by administering the subject an active compound in an amount effective to treat the leukemia. The active compound comprises FdUMP[10] or a pharmaceutically acceptable salt thereof.... Agent:

20130041019 - Sdf-1 binding nucleic acids: The present invention is related to an L nucleic acid that binds to an SDF-1.... Agent: Noxxon Pharma Ag

20130040907 - Compounds, compositions and methods of using same for modulating uric acid levels: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences Inc.

20130040906 - Inhibitors of human ezh2, and methods of use thereof: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2,... Agent:

20130040908 - Substitution derivatives of n6-benzyladenosine-5' -monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds: Substitution derivatives of N6-benzyladenosine-5′-monophosphate of the general formula I, wherein (R)n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C1 to C8 alkyl, C1 to C8 alkoxy, amino, halogen, hydroxy, mercapto and... Agent: Univerzita Palackeho V Olomouci

20130040909 - Compositions including triciribine and one or more platinum compounds and methods of use thereof: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent:

20130040910 - Method of treating vitamin b12 deficiency: A novel method and composition for treating vitamin B12 deficiency mammals that fail to respond to oral vitamin B12 therapy.... Agent: Emisphere Technologies, Inc.

20130040911 - Adhesion-preventing material: The CMC structure of the present invention is substantially composed of carboxymethyl celluloses, comprising an acid carboxymethyl cellulose and an alkaline metal carboxymethyl cellulose in a mixed state. The method of production of the present invention comprises subjecting the alkaline metal (or acid) carboxymethyl cellulose structure to an acid (or... Agent: Hogy Medical Co., Ltd.

20130040912 - Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders: The invention relates to compounds of formula (I) R1 is methyl, n-hexyl, aminoethyl, methylaminoethyl, ethylaminoethyl, dimethylaminoethyl, acryloylaminoethyl, methacryloylaminoethyl, methoxyethyl, ethoxyethyl, d-C4-alkyl-sulfonyl, acryloyl, or methacryloyl; or R1 is aminoethyl, acryloyl or acryloylaminoethyl carrying a linker and a tag, and R2 and R3, independently of each other, are hydrogen or CrC4-alkyl, or... Agent: University Of Basel

20130040913 - Omega 3 fatty acidfor use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels: The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade... Agent: Pivotal Therapeutics Inc.

20130040914 - Prodrugs of an hiv reverse transcriptase inhibitor: Compounds of Formula I are described: (I), wherein RP and RQ are defined herein. The compounds transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in... Agent:

20130040915 - Pharmaceutical composition: An injectable pharmaceutical composition contained in a receptacle for injection into a human, which comprises a solution of zoledronic acid or the salts thereof, a solvent and a pH regulator.... Agent: Capital, Business Y Gestion De Finanzas, S.l.

20130040916 - Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Esperion Therapeutics, Inc.

20130040917 - Phenazopyridine compounds: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.... Agent: Pinnacle Pharmaceuticals, Inc.

20130040918 - Tetracycline compositions: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.... Agent: Rempex Pharmaceuticals, Inc.

20130040919 - C-nitroso-derived nitroxyl donors: e

20130040920 - Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and/or pharmaceutical product, and method for enhancing the potential of resveratrol:

20130040921 - Anticancer steroidal lactones unsaturated in position 7 (8): A compound of general formula (I), wherein R1-R17 and the ------ line take various meanings for use in the treatment of cancer.... Agent: Pharma Mar, S.a.

20130040922 - Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.... Agent: Trimel Pharmaceuticals Corporation

20130040923 - Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.... Agent: Trimel Pharmaceuticals Corporation

20130040924 - Bridged polycyclic compound based compositions for the inhibition and amelioration of disease: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Allaccem, Inc.

20130040925 - Osmium (ii) arene azo anti-cancer complexes: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.... Agent: University Of Warwick

20130040927 - Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events: A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of... Agent: Pivotal Therapeutics Inc.

20130040930 - Novel amide derivative and use thereof as medicine: c

20130040929 - Novel prolylcarboxypeptidase inhibitors: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.... Agent: Merck Sharp & Dohme Corp.

20130040931 - Amino heteroaryl compounds as beta-secretase modulators and methods of use: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1,... Agent: Amgen Inc.

20130040933 - Azaindoles as janus kinase inhibitors: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof. Compounds of formula I are inhibitors of Janus kinases and as such are useful for the treatment of various diseases and conditions mediated by said enzymes, such as rheumatoid arthritis, asthma, COPD, ALS, and the like.... Agent:

20130040932 - Substituted aryl sulfone derivatives as calcium channel blockers: A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with,... Agent: Merck Sharp & Dohme Corp.

20130040928 - Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics: s

20130040926 - Novel compound:

20130040934 - Spirocyclic compounds and their use as therapeutic agents and diagnostic probes: The invention relates to new triazines (G=Q=U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E1 is CR4 or N; X1 is CHR4,... Agent:

20130040935 - Cyclic keto-enols for therapy: The invention relates to 5′-biphenyl-substituted cyclic ketoenols for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.... Agent: Bayer Intellectual Property Gmbh

20130040936 - 1,4-oxazepines as bace1 and/or bace2 inhibitors: e

20130040937 - Inhibitors for treating and preventing heart failure in felines: The present invention relates to an If blocker or a pharmaceutically acceptable salt thereof and methods of using the If blocker or a pharmaceutically acceptable salt thereof to treat and/or prevent heart failure (HF) in a feline patient. The invention also relates to improving the quality of life, improving the... Agent: Boehringer Ingelheim Vetmedica Gmbh

20130040938 - Compositiions for treating cognitive disorders: e

20130040939 - Oral suspension formulations of esclicarbazepine acetate: An oral suspension formulation comprising eslicarbazepine acetate and a pharmaceutically acceptable liquid vehicle.... Agent: Bial - Portela & Ca, S.a.

20130040940 - Mercaptoamidine derivatives and methods of use:

20130040941 - Benzodiazepine compound and pharmaceutical composition:

20130040942 - Salts of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing... Agent: Essentialis, Inc.

20130040943 - Tricyclic pyridyl-vinyl pyrroles as par1 inhibitors: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use... Agent: Sanofi

20130040944 - Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction: Pyrrole compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.... Agent: Vanderbilt University

20130040945 - Certain chemical entities, compositions, and methods: Chemical entities that are arctigenin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.... Agent:

20130040946 - Substituted imidazopyrimidines and triazolopyrimidines: The invention relates to substituted imidazo- and triazolopyrimidines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of haematological disorders, preferably of leucopenias and neutropenias.... Agent: Bayer Intellectual Property Gmbh

20130040947 - Trkb agonists and methods of use: Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-di-hydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity)... Agent: Emory University

20130040948 - Novel benzodioxole piperazine compounds: m

20130040949 - Type ii raf kinase inhibitors: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.... Agent: Dana-farber Cancer Institute, Inc.

20130040950 - Multisubstituted aromatic compounds as inhibitors of thrombin: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or... Agent: Verseon Corporation

20130040952 - Influenza virus inhibitors that disrupt nucleoprotein trimerization: Methods for identifying agents capable of disrupting a salt bridge in an influenza A virus nucleoprotein corresponding to the E339 . . . R416 salt bridge in SEQ ID NO:1, and thus the trimerization of the NP protein; and uses of such agents, e.g., small molecules and peptides, for inhibiting... Agent: Academia Sinica

20130040951 - Prophylactic or therapeutic agent for cancer: t

20130040953 - Promotion of wound healing: The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and/or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.... Agent:

20130040954 - Pleuromutilin derivatives for the treatment of diseases mediated by microbes: Pleuromutilin derivative compounds of the following formula, and uses thereof for the treatment of diseases mediated by microbes, are disclosed:... Agent:

20130040955 - 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders: The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The... Agent: Boehringer Ingelheim International Gmbh

20130040956 - Process for the preparation of stable, crystalline (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid: e

20130040957 - Deuterium-enriched pyrimidine compounds and derivatives: and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular... Agent:

20130040958 - Imatinib mesylate preparation procedure: d

20130040959 - Heterocyclic quinolizine derived m1 receptor positive allosteric modulators: The present invention is directed to novel 3-oxo-2,3-dihydropyrazolo[4,3-c]quinolizine derived compounds of generic formula (I) or a pharmaceutically acceptable salt thereof, which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or... Agent:

20130040960 - Ophthalmic gel of gatifloxacin and preparation method thereof: An ophthalmic gel of gatifloxacin and the preparation method thereof are disclosed. The gel comprises gatifloxacin or its pharmaceutical salts, matrix and water. Said matrix is one or more selected from carbomer, mixture of carbomer and HPMC, and sodium hyaluronate.... Agent: Shenyang Xingqi Pharmaceutical Co., Ltd.

20130040961 - Oligomer modified diaromatic substituted compounds: Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic... Agent: Nektar Therapeutics

20130040962 - P38 map kinase inhibitors: There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis.... Agent:

20130040964 - 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors: The present invention refers to the field of chemical compounds bearing a 1,2,3-triazole ring of formula (I) and possessing guanidino and carboxylic groups or their isosteres, their preparation by Cu-catalyzed “click-chemistry”, and medical-diagnostic use in pathologies where angiogenesis is altered, for example pathologic conditions of tumor origin, tumor metastasis, osteoporosis,... Agent: Universita' Degli Studi Di Firenze

20130040963 - Compounds, compositions and methods of using same for modulating uric acid levels: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences, Inc.

20130040965 - Aminotetralin compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid... Agent: Theravance, Inc.

20130040966 - Pharmaceutical formulations containing dopamine receptor ligands: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.... Agent: Forest Laboratories Holdings Ltd.

20130040967 - 4'-demethylepipodophyllotoxin derivative, preparation method and use thereof: A 4′-demethylepipodophyllotoxin derivative of formula(III) having anti-tumor activity is provided. After the activation of hydroxyl in position C4 of 4′-demethylepipodophyllotoxin, tetramethylpyrazine is introduced by transamination to obtain the 4′-demethylepipodophyllotoxin derivative which is preferably used to inhibit gastric cancer line BGC-823.... Agent: Hubei University Of Technology

20130040968 - Fat or oil composition: 4

20130040969 - Fungicidal mixtures based on azolopyrimmidinylamines: Fungicidal mixtures based on azolopyrimidinylamines.... Agent: Basf Se

20130040970 - Co-crystals of a triazolo [4,5-d] pyrimide platelet aggregation inhibitor: The present invention relates to novel co-crystal forms of the compound of formula (I); wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their... Agent: Astrazeneca Ab

20130040971 - 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders: The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The... Agent: Boehringer Ingelheim International Gmbh

20130040972 - Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) a pyrimidylaminobenzamide compound; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukemia, especially chronic myelogenous leukemia, comprising administering to the animal at least... Agent:

20130040973 - Jak pi3k/mtor combination therapy: Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.... Agent: Novartis Pharma Ag

20130040974 - Piperidine inhibitors of janus kinase 3: The present invention relates to new piperidine inhibitors of Janus kinase 3 activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20130040975 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing... Agent: Neurocrine Biosciences, Inc.

20130040976 - Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation... Agent: Samumed, LLC

20130040977 - Pro-neurogenic compounds: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such... Agent: Board Of Regents Of The University Of Texas System

20130040978 - Spiro isoxazoline compounds as sstr5 antagonists: Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.... Agent:

20130040980 - Cci-779 concentrate formulations: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.... Agent: Wyeth LLC

20130040979 - Ccr1 inhibitors useful for the treament of multiple myeloma and other disorders: The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.... Agent: Millennium Pharmaceuticals, Inc.

20130040981 - Pyridylvinylpyrazoloquinolines as par1 inhibitors: e

20130040982 - Oral sustained release formulation of huperzine a: Sustained-release formulations comprising huperzine A are disclosed herein. The formulations are for oral administration, and contain a carrier which comprises native albumin. Unit dosage forms of the formulations, and kits comprising such unit dosage forms are also disclosed herein. Methods utilizing the formulations for treating a medical condition treatable by... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20130040984 - 7-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors: which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies,... Agent: Glaxo Group Limited

20130040983 - Raf kinase inhibitors: Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinae mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.... Agent:

20130040985 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: The present application discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the application discloses the use of these compounds, a method for therapy and to pharmaceutical compositions comprising these compounds.... Agent: Neurosearch A/s

20130040986 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.... Agent:

20130040987 - Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders: wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.... Agent: Armetheon, Inc.

20130040988 - 3-amino-pyridine derivatives for the treatment of metabolic disorders: e

20130040989 - 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts: There is provided a salt of 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid selected from the group consisting of citrate, hemi-fumarate, maleate, L-tartrate, mesylate, hydrochloride, potassium, and sodium salts.... Agent: Ferrer Internacional S.a.

20130040990 - Synthesis of dgjnac from d-glucuronolactone and use to inhibit alpha-n-acetylgalactosaminidases: A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibitor of -hexosaminidases. Synthesis and activity of L-DGJNAc IL is also shown. The use... Agent: The Chancellor, Masters And Scholars Of The University Of Oxford

20130040991 - Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide: The invention provides gemfibrozil for use in adjusting the effect of a CYP2C8 and/or OATP substrate drug, wherein gemfibrozil is administered in an amount of less than 1200 mg/day. The invention also provided a pharmaceutical composition comprising gemfibrozil providing a significant improvement to the plasma profiles of a CYP2C8 and/or... Agent:

20130040992 - Substituted 2, 6-diamino-3, 5-dicyano-4-aryl-pyridines and their use as adenosine-receptor-selective ligands: e

20130040993 - Fungicide hydroximoyl-heterocycles derivatives: The present invention relates to hydroximoyl-heterocycle derivatives, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent:

20130040994 - Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using... Agent:

20130040995 - Novel compounds: e

20130040996 - Composition for treating atherosclerosis and a preparation method thereof: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not... Agent: Kaohsiung Medical University

20130040997 - Novel pyridine carboxylic acid based compound used as a p2x1 and p2x3 receptor antagonist, a production method for the same and a composition comprising the same: Provided are a novel pyridine carboxylic acid based compound used as a P2X1 and P2X3 receptor antagonist, a production method for the same and a composition comprising the same. The compound according to the present invention is a powerful antagonist of P2X1 and P2X3 receptors, and hence can be used... Agent: Gwangju Institute Of Science And Technology

20130040998 - Fluorinated hdac inhibitors and uses thereof: Fluorinated deacetylase inhibitors of the general formulae (I), (II), and (III): and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase activity as described herein (e.g., cancer,... Agent: President And Fellows Of Harvard College

20130040999 - New compounds for alleviation, prevention or treatment of osteoporosis, the preparation thereof and pharmaceutical composition comprising the same: The present invention provides novel compounds of Chemical Formula I, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, a preparation thereof and a composition for the alleviation, prevention or treatment of osteoporosis, comprising thereof in an effective amount, and a method for alleviating, preventing or treating osteoporosis.... Agent: Ewha University-industry Collaboration Foundation

20130041000 - Novel azole compound: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic... Agent: Ajinomoto Co., Inc.

20130041001 - Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases: Nitrate esters and diazeniumdiolate derivatives of valsartanamide are described. They have valuable properties in the treatment of vascular and metabolic diseases.... Agent:

20130041002 - Denibulin di-hydrochloride: t

20130041003 - Bendamustine pharmaceutical compositions: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.... Agent:

20130041004 - Liquid formulations of bendamustine: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.... Agent:

20130041005 - Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers: a

20130041006 - Pharmaceutical composition for intracellar acidification with cis-urocanic acid: A pharmaceutically acceptable agent able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is... Agent: Biocis Pharma Oy

20130041007 - Selective androgen receptor modulators: This invention provides compounds of Formula (I), (Ia), (Ib), (Ic), (II), (IIa) or (III) and or salts thereof, pharmaceutical compositions comprising a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa) or (III) and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated... Agent:

20130041008 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Onyx Therapeutics, Inc.

20130041020 - Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals: The invention relates to methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid.... Agent: Hill's Pet Nutrition, Inc.

20130041021 - Methods of improving the pharmacokinetics of doxepin: Methods of improving the pharmacokinetics of doxepin in a patient.... Agent: Somaxon Pharmaceuticals, Inc.

20130041022 - Glyceollins suppress androgen-responsive prostate cancer: The present disclosure demonstrates the molecular effects of glyceollins on human prostate cancer cell LNCaP to further elucidate its potential effects on prostate cancer prevention. The glyceollins inhibited LNCaP cell growth similar to that of the soy isoflavone genistein. The growth inhibitory effects of the glyceollins appeared to be due... Agent: The Administrators Of The Tulane Educational Fund

20130041023 - Composition for preventing or treating rotavirus infection comprising licorice extract: The present invention relates to a composition for preventing or treating rotavirus infection, comprising a licorice extract, fractions thereof or compounds separated therefrom. The licorice extract, fractions thereof or compounds separated therefrom have anti-rotavirus effects and exhibit not only virucidal effects against various rotaviruses, but also the effect of inhibiting... Agent:

20130041024 - Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in... Agent: Hill's Pet Nutrition, Inc.

20130041025 - Compositions and methods for treating hair loss, hair thinning, and hair color loss: Described herein are compositions including prostaglandin analogs including prostamides and methods for using these compositions for increasing eyelash and eyebrow growth and hair growth on the scalp.... Agent: Allergan, Inc.

20130041026 - Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.... Agent: Xenoport, Inc.

20130041027 - Organo-arsenoxide compounds and use thereof: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.... Agent: Newsouth Innovations Pty Limited

20130041028 - Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).... Agent: Brookhaven Science Associates

20130041029 - Methods and lipid compositions for promoting development of gut flora: Disclosed is a method of inducing and promoting development of beneficial gut flora in a subject and/or of reducing the frequency and duration of crying periods in a subject, the method comprises administering to the subject a lipid composition comprising a vegetable-derived fat source, wherein the fat source is a... Agent: Enzymotec Ltd.

20130041030 - Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents (psoa): The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds... Agent: Ecolab Usa Inc.

20130041031 - Fatty acid desaturases from primula: The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes... Agent:

20130041032 - Fatty acid desaturases from primula: The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes... Agent:

20130041033 - Composition comprising vitamin u as active ingredient for healing skin wound: Disclosed is a composition comprising vitamin U as an active ingredient, more precisely a composition for repairing the skin wound that contains vitamin U as an active ingredient. The composition demonstrates excellent wound healing and skin wound repairing effects.... Agent: Cuskin Co., Ltd.

20130041034 - Treatment of pain with topical diclofenac compounds: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.... Agent:

20130041035 - Topical application of adapalene for the long-term treatment of acne vulgaris: Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two... Agent: Galderma Research & Development

20130041036 - Ferulic acid as feed supplement in beef cattle to promote animal growth and improve the meat quality of the carcass and the meat: The present disclosure comprises a natural method of feed supplement to beef cattle, with a maize extract obtained from the nixtamalization process with a high content of ferulic acid and its salts, for a period of 30 days in the final phase of the feedlot. Use of this dietary supplementation... Agent: Biokab, S.a. De C.v.

20130041037 - Therapeutic applications of fatty acid amide hydrolase inhibitors: Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.... Agent: The United States Of America As Represented By The Secretary, Department Of Health And Human Service

20130041038 - Hyaluronic acid-based gels including lidocaine: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including... Agent: Allergan Industrie, Sas

20130041039 - Hyaluronic acid-based gels including lidocaine: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including... Agent: Allergan Industrie, Sas

20130041040 - Solid pharmaceutical composition for buccal administration of agomelatine: The invention relates to a solid buccal pharmaceutical composition comprising agomelatine intended for systemic action.... Agent: Les Laboratoires Servier

20130041041 - Microwave remediation of medical wastes: Methods, devices, and remediation compositions for the microwave remediation of medical wastes are provided. The remediation compositions include a microwave active fluid including a microwave active liquid, a microwave enhancer, and a viscosity modifying agent. Methods include immersing medical waste in the remediation composition and then irradiating the medical waste... Agent: Ashwin-ushas Corporation

20130041042 - Polymeric compositions and articles of manufacture for wound and burn treatment and other uses: Polymeric compositions for enhanced wound or burn treatment characteristics and other medical, industrial, recreational and domestic applications can be formulated as biocompatible, elastomeric, polymers. Such compositions can be used as advanced wound or burn care dressings or for other medical and non-medical purposes. The compositions generally comprise a polymeric component... Agent:

20130041043 - Excipient from trigonella foenum-graceum seeds and process for preparation thereof: An excipient from Trigonella foenum-graceum seeds and a process for preparation thereof is disclosed. The excipient obtained from Trigonella foenum-graceum seeds, comprising insoluble and soluble dietary fibers can be used in various pharmaceutical or cosmetic compositions and food, nutritional or dietary preparations.... Agent: Rubicon Research Private Limited

20130041044 - Phase separated composite: A composite is disclosed. The composite comprises a first conjugate of a polymer and a first phenol-containing moiety, and a second conjugate of a gelatin or collagen and a second phenol-containing moiety, wherein the polymer is selected so that the first conjugate is less cell-adhesive than the second conjugate, at... Agent: Agency For Science, Technology And Research

20130041045 - Functionalized diphenolics and absorbable polymers therefrom: c

20130041046 - Sweet flavor modifier: The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of compositions.... Agent: Senomyx, Inc.

20130041047 - Urinary methylation markers for bladder cancer: A method of detecting bladder cancer is described using hypermethylated urinary markers.... Agent: Aros Applied Biotechnology As

20130035279 - Method and a system for producing thermolabile nanoparticles with controlled properties and nanoparticles matrices made thereby: This disclosure relates to a method and a system of producing nanoparticles and nanoparticle matrices of thermolabile, biocompatible matrix materials, like lipids and biopolymers with controlled properties. A prototype pulse-heat aerosol system is described for single-step production of free, thermolabile nanoparticles with sufficient control over size, morphology and crystallinity with... Agent: Indian Institute Of Technology, Bombay

20130035280 - Method and means for identifying substances which inhibit ige production: The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of... Agent:

20130035282 - Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused... Agent:

20130035281 - Pharmaceutical composition, methods for treating and uses thereof: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or... Agent: Boehringer Ingelheim International Gmbh

20130035283 - Engineered opsonin for pathogen detection and treatment: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding... Agent: President And Fellows Of Harvard College

20130035284 - Small-molecule inhibitors of dengue and west nile virus proteases: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.... Agent: The Board Of Regents Of The University Of Texas System

20130035285 - Novel glucagon analogues: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in... Agent: Novo Nordisk A/s

20130035286 - Pharmaceutical composition comprising cyclic somatostatin analogues: The present invention describes parenteral pharmaceutical compositions comprising a somatostatin analogue and novel somatostatin analogues.... Agent: Novartis Ag

20130035287 - Transient immortalization: The invention relates to a method for transiently immortalizing cells according to which immortalization proteins are introduced into the cells from outside. The invention also relates to a method for producing cells according to which organ-related cells are transiently immortalized by the exogenous supply of immortalization proteins and are remortalized... Agent: Heart Biosystems Gmbh

20130035288 - Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood... Agent:

20130035289 - Pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (prl)-growth hormone (gh)-placental lactogen (pl)-family protein: The present disclosure relates to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of plasminogen activator inhibitor 1 (PAI-1) expression, which composition comprises: A) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH)-placental lactogen (PL)-family... Agent: Universite De Liege

20130035290 - Chitinase-3-like protein 1 as a biomarker of recovery from kidney injury: The present invention provides compositions and methods for the detection, treatment, and prevention of a kidney injury. The invention relates to the discovery that chitinase 3-like 1/Brp-39/YKL-40 serves as both a biomarker for the degree of kidney injury and a critical mediator of a reparative response in the kidney.... Agent: Yale University

20130035291 - Obtainment of bioactive products from cocoa having inhibitory activity against the pep enzyme and antioxidant and/or antineurodegenerative activity: The present invention relates to the production of bioactive products from raw plant matter, namely cocoa extracts. The said products have one or more biopeptides with prolyl endopeptidase (PEP) enzyme inhibitory activity in vitro and/or antioxidant and/or antineurodegenerative capacity in vivo and can be used in dietetics and in the... Agent: Biopolis, S.l.

20130035293 - Compositions and methods for modulating dopamine neurotransmission: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.... Agent: Centre For Addiction And Mental Health

20130035292 - Nmda receptors modulators and uses thereof: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of... Agent:

20130035294 - Neuromedin and fn-38 peptides for psychotic diseases: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with... Agent: Amylin Pharmaceuticals, LLC

20130035295 - Use of peptide epoxyketones for metastasis suppression: The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics... Agent:

20130035296 - Therapeutic peptides: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the substituting groups in the β amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms,... Agent: Lytix Biopharma As

20130035297 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Onyx Therapeutics, Inc.

20130035299 - Antimicrobial composition based on botanical extracts from oil palm vegetation liquor: The present invention provides an antimicrobial composition comprising compounds extracted from the vegetation liquor of the palm oil milling process has been suggested. This composition is rich in antioxidants and exhibits enhanced antimicrobial activity and bactericidal effect against a number of micro-organisms.... Agent: Malaysian Palm Oil Board

20130035298 - Pharmaceutical composition, methods for treating and uses thereof: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.... Agent: Boehringer Ingelheim International Gmbh

20130035301 - Cdc7 kinase inhibitors and uses thereof: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or... Agent: Sloan-kettering Institute For Cancer Research

20130035300 - Method of using pomegranate extracts for increasing prostate specific antigen doubling time: A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to... Agent:

20130035302 - Use of yessotoxin and analogues and derivatives thereof for treating and/or preventing neurodegenerative diseases linked to tau and beta amyloid: The present invention is in the field of biomedicine pharmaceutical chemistry. Specifically, it refers to the use of yessotoxin, its derivatives and analogues, for the preparation of a medicinal drug for the prevention and/or treatment of neurodegenerative diseases related to abnormal levels of Tau and β-amyloid proteins such as, for... Agent: Universidade De Santiago De Compostela

20130035303 - Compositions and methods for control of sand flies and other blood sucking insects: The invention relates to a new rapid release oral formulation of fipronil or imidacloprid for the effective control of blood-sucking insect populations. Embodiments of the invention relate to their use by incorporation into a feed-through formulation that can be administered orally to host animals such as birds, goats, dogs, and... Agent: Genesis Laboratories, Inc.

20130035304 - Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders: This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory... Agent:

20130035305 - Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases: The invention relates to the use of a combination of active ingredients, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or... Agent:

20130035365 - Anti-sense oligonucleotides targeted against exon 9 of il-23r alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23Rα gene. Exon 9 skipping of the IL23Rα gene ultimately causes specific induction of a novel soluble truncated IL-23Rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8)... Agent: Medical Diagnostic Laboratories LLC

20130035367 - Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndrome: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length... Agent: Rosalind Franklin University Of Medicine And Science

20130035370 - Compositions and methods for modulation of lmna expression: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are... Agent: Isis Pharmaceuticals, Inc.

20130035369 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified... Agent: Isis Pharmaceuticals, Inc.

20130035371 - Lipid formulated dsrna targeting the pcsk9 gene: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.... Agent:

20130035374 - Microrna induction of pluripotential stem cells and uses thereof: Compositions and methods for inducing the formation of an induced pluripotential stem (iPS) cell from a somatic cell are disclosed. The compositions comprise miR 302-367 cluster and valproic acid. Further disclosed are methods for treatment of a disease or condition in a subject through the use of the compositions.... Agent:

20130035366 - Modulation of hepatitis b virus (hbv) expression: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.... Agent:

20130035368 - Oligonucleotide compounds comprising non-nucleotide overhangs: The invention relates to siRNA compounds comprising one non-nucleotide moiety covalently attached to at least one of the sense or antisense strands to down-regulate the expression of human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier and to methods of treating and/or... Agent:

20130035372 - Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders... Agent: Curna, Inc.

20130035373 - Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases... Agent: Curna, Inc.

20130035375 - Gene re-cycling: Corroborating the Nature's hidden biological phenomena, like ethnicity, cyclic occurrence of diseases, re-appearance of extinct animals, Biblical citations etc., with modern literature on transgenic plants/animals, human genomic studies. gene sequencing, etc. it is hypothesized that genes of flora and fauna are recycled from generation to generation through immortal DNA. It... Agent: Dr. Mrs. Thankam Mathew, M.v.sc., Ph.d.

20130035376 - Mcp-1 binding nucleic acids: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115... Agent: Noxxon Pharma Ag

20130035306 - Process for preparing purine nucleosides: The present invention provides for the preparation β-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein... Agent: Genzyme Corporation

20130035308 - Complex combining an organic silicon derivative with hyaluronic and acid calibrated fragments, for preventive and repairing action of cutaneous damages: e

20130035307 - Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers: Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEs”). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.... Agent: University Of Utah Research Foundation

20130035309 - Ophthalmic sealant composition and method for use: A polymeric hydrogel sealant specifically formulated to seal ophthalmic wounds is provided. The sealant is formed by mixing two aqueous solutions. The first aqueous solution comprises an oxidized dextran having a specific average molecular weight range and oxidation level and the second aqueous solution comprises a 4-arm polyethylene glycol having... Agent: Actamax Surgical Materials ,llc

20130035310 - Piperidine and piperazine phenyl sulfonamides as modulators of ion channels: The present invention relates to piperidine and piperazine phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.... Agent: Vertex Pharmaceuticals Incorporated

20130035312 - Cathepsin cysteine protease inhibiors: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.... Agent: Merck, Sharp & Dohme, Corp.

20130035311 - Prochelators for inhibiting metal-promoted oxidative stress: The present invention provides compounds of Formula I along with compositions containing the same and methods of use thereof in treating oxidative stress.... Agent:

20130035313 - Nucleoside phosphonate salts: The present invention relates to compounds and methods for treating viral diseases. Some compounds of the invention are described by Formula I: (I), wherein M+ is Na+, Li+, K+, Ca2+, Mg2+, or NRcRdReRf+ and Rc, Rd, Re and Rf are each independently hydrogen or C1-5 alkyl, or a stereoisomer, a... Agent:

20130035315 - Crystallization method and bioavailability: Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.... Agent:

20130035314 - Methods and kits for detecting risk factors for development of jaw osteonecrosis and methods of treatment thereof: Methods of and kits for determining the pharmacogenetic, pharmacokinetic and cellular basis of bisphosphonate-induced osteonecrosis of the jaw (BONJ) involve associating particular proteins and particular single nucleotide polymorphisms with a risk for developing BONJ after receiving bisphosphonate treatment. Methods and kits for identifying the genetic basis for a patient's predisposition... Agent:

20130035316 - Pharmaceutical composition comprising metformin and rosuvastatin: This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood... Agent: Bcworld Pharm. Co., Ltd.

20130035317 - Di-aspirin derivatives: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.... Agent:

20130035318 - C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity: e

20130035319 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: A combination which comprises (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane. In the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent:

20130035320 - Pyrrolidine derivatives: Novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formulae (I) and (I′) are effective for the prevention and/or treatment of diseases in which the number, activity, and movement of inflammatory cells is implicated.... Agent: Chiesi Farmaceutici S.p.a.

20130035321 - Compounds for the treatment of ocular cancer: In one aspect, the instant invention provides novel compounds and pharmaceutical compositions useful for treating proliferative diseases such as cancer. In another aspect, the invention provides methods of using certain compounds in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular... Agent: Sloan-kettering Institute For Cancer Research

20130035322 - Gold complexes: Gold (I) hydroxide complexes of the form Z-Au-OH and digold complexes of the form Z—Au-(μOH)—Au—Z where groups Z are two electron donors are provided. The groups Z may be carbenes, for example nitrogen containing heterocyclic carbenes (NHCs), phosphines or phosphites. The complexes can be used as catalysts, for example in... Agent: University Court Of The University Of St. Andrews

20130035324 - Heterocyclic compounds and uses thereof: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.... Agent:

20130035325 - Kinase inhibitors: Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.... Agent: The Regents Of The University Of California

20130035323 - Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy: t

20130035326 - Biaryl compounds and methods of use thereof: Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.... Agent: Ambit Biosciences Corporation

20130035327 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent:

20130035328 - Antiviral compounds and methods: The invention relates to compounds having antiviral activity and methods utilizing the compounds to treat viral infections.... Agent:

20130035329 - Therapeutically active compositions and their methods of use: Compounds and compositions comprising compounds useful in the treatment of cancer are described herein.... Agent:

20130035330 - Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats: The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or... Agent: Boehringer Ingelheim Vetmedica Gmbh

20130035331 - Thiazole and oxazole kinase inhibitors: The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are... Agent: Ab Science

20130035332 - Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(ih)-ones as positive allosteric modulators of mglur2: The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The... Agent:

20130035333 - Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders: The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.... Agent: The Regents Of The University Of California

20130035335 - 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.... Agent: Afraxis, Inc.

20130035336 - Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer: A combination of a CDK4/8 inhibitor and an mTOR inhibitor for the treatment of cancer.... Agent: Novartis Ag

20130035334 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20130035337 - Fused bicyclic heteroaryl derivative: R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently... Agent: Daiichi Sankyo Company, Limited

20130035339 - Apoptosis signal-regulating kinase inhibitors: wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical... Agent: Gilead Sciences, Inc

20130035338 - Eyelid treatment: The current application is directed topical treatments that improve facial appearance by causing eyelids to naturally open more widely, or be more fully raised, as well as to treatment of ptosis and other eyelid-related conditions. These topical treatments include one or more of travoprost, dorzolamide hydrochloride, timolol maleate, unoprostone, latanoprost,... Agent:

20130035340 - Sgc stimulators or sgc activators alone and in combination with pde5 inhbitors for the treatment of cystic fibrosis: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment... Agent: Bayer Intellectual Property Gmbh

20130035341 - Macrocyclic integrase inhibitors: e

20130035342 - Compound suitable for the treatment of synucleopathies: The present invention relates to a compound of formula (I): Wherein R1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl... Agent: Neuropore Therapies, Inc.

20130035343 - Combination of organic compounds: A pharmaceutical combination comprising 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one and at least one mTOR inhibitor and the pharmaceutical combination for use in treating or preventing a proliferative disease.... Agent: Novartis Ag

20130035344 - Pharmaceutical composition for oral administration: The present invention relates to a solid pharmaceutical composition for oral administration, containing the following components (A) and (B): 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (compound a) or an acid addition salt thereof, and (B) citric acid. An improvement is achieved in the dissolubility of the compound a, which is useful as a therapeutic agent... Agent: Kowa Co., Ltd.

20130035345 - Solid dispersion formulations and methods of use thereof: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.... Agent: Zalicus Pharmaceuticals Ltd.

20130035346 - Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes... Agent: Astrazeneca Ab

20130035347 - Aromatic bycyclic derivatives as cxcr4 receptor modulators: The present invention relates to novel aromatic bicyclic derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the CXCR4 receptor.... Agent:

20130035348 - Antimetastatic compounds: Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the MET receptor.... Agent: Brigham Young University

20130035349 - Pyrazolopyrimidinone kinase inhibitor: The present invention provides a novel pyrazolo[3,4-d]pyrimidin-4-one, specifically a derivative of 1-(pyridine-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one. This compound is a kinase inhibitor that shows unexpected anti-proliferative activity against cells, including against tumor cells, and anti-tumor activity in xenograft tumor models. The compound or a suitable salt or prodrug thereof is useful for the treatment... Agent: Agennix Ag

20130035350 - Novel quinazoline derivatives: This disclosure concerns novel quinazoline compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful anticancer agents, especially in inhibiting the function of the EGF receptor tyrosine kinases, HER1 tyrosine kinase, and HER2 tyrosine kinase. Thus, the disclosure also concerns a... Agent:

20130035351 - Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.... Agent: Southwest Research Institute

20130035352 - Gaba conjugates and methods of use thereof: In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs.... Agent:

20130035354 - Aryl pyridine as aldosterone synthase inhibitors:

20130035353 - Drugs for the treatment of sarcoglycanopathies: Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used for the preparation of a medicinal product intended to treat sarcoglycanopathies.... Agent: Genethon

20130035356 - Crystal of diamine derivative and method of producing same: An object of the present invention is to provide a novel crystal form of a compound that has an inhibitory effect on activated blood coagulation factor X and is useful as a pharmaceutical compound for prevention and/or treatment of thrombotic and/or embolic diseases. The present invention provides a novel crystal... Agent: Daiichi Sankyo Company, Limited

20130035355 - Prasugrel in micronized, crystalline form and pharmaceutical composition thereof: The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions.... Agent: Ratiopharm Gmbh

20130035357 - Compositions and methods for preventing joint destruction in osteoarthritis: The present invention is methods for inhibiting collagen destruction in joints of osteoarthritis patients. The methods are based on use of rexinoid compounds, in particular bexarotene, and their activity to inhibit synthesis of matrix metalloproteinases (MMPs) in affected tissue.... Agent: Trustees Of Dartmouth College

20130035358 - Bis aromatic compounds for use as ltc4 synthase inhibitors: wherein E1, E2a, E2b, E2c, E4, D1, D2, D3, L1, Y1, L2 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of... Agent:

20130035359 - Compositions containing aromatic aldehydes and their use in treatments: Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.... Agent:

20130035360 - Novel water soluble furoxan derivatives having antitumor activity: Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described.... Agent: Humanitas Mirasole S.p.a.

20130035361 - Use of ergothioneine as a preservative in foods and beverages: The invention relates to the novel use of ergothioneine and preferably, L ergothioneine, as a nutritional additive and preservative in foods, medicines, and/or beverages. According to the invention, the powerful antioxidant ergothioneine was found to be very stable over time in and to have no deleterious effects on taste or... Agent:

20130035362 - Stable anti-inflammatory solutions for injection: The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.... Agent: Omeros Corporation

20130035363 - Thalidomide analogs: Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.... Agent: P2d Inc.

20130035364 - Benzylidene-indolinone compounds and their medical use: a

20130035377 - Tranylcypromine derivatives as inhibitors of histone demethylases lsd1 and/or lsd2: Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong... Agent: Fondazione Ieo

20130035378 - Film delivery system for tetrahydrolipstatin: The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided... Agent: Monosol Rx LLC

20130035382 - Anti-viral compounds: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.... Agent: Kineta, Inc.

20130035379 - Compositions for inhibiting protine-directed protein kinase fa/glycogen synthesis kinase 3 alpha and use thereof: The invention provides a composition for inhibiting proline-directed protein kinase FA/glycogen synthase kinase 3α (PDPK FA/GSK-3α), experiments verified that the composition can effectively inhibit the PDPK FA/GSK-3α. In addition, inhibition of PDPK FA/GSK-3α can improve the clinical efficacy of cancer treatment and cure rate.... Agent: National Tsing Hua University

20130035380 - Process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers and a stable composition thereof: The present invention relates to a process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers of the type A and type B, of more than 90% purity as gallic acid equivalent which comprises the steps of removing the organic solvent from the extract to produce the... Agent: Akay Flavours & Aromatics Pvt Ltd.

20130035381 - Virus-inactivating composition containing low-molecular weight compound and arginine: The invention provides a virus-inactivating composition with pH of 3.8 to 5.5, containing (A) 0.02 to 0.3 M arginine and (B) a component such as 0.01 to 10 mM flavonoid, polyphenol, or ascorbic acid derivative, 0.005 to 5 mass % of an arginine derivative, and 0.1 to 2.5 mass %... Agent:

20130035383 - Liquid/liquid extraction: The invention relates to a method for the extraction of all unsaponifiable fraction contained in a vegetable oil, an oil originating from a micro-organism or a vegetable butter or in a co-product from the vegetable oil refining industry, such as deodorisation discharge. The method includes at least: A) a step... Agent: Laboratoires Expanscience

20130035384 - Orally dispersible tablet: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of... Agent: Takeda Pharmaceutical Company Limited

20130035385 - Orally dispersible tablet: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of... Agent: Takeda Pharmaceutical Company Limited

20130035386 - Bis[thiohydrazide amide] compounds for treating leukemia: Certain bis[thio-hydrazide amide]-related compounds are found to be surprisingly effective at treating with leukemia, e.g., acute myeloid leukemia (AML). Methods of treating a subject with AML including administering bis[thio-hydrazide amide]-related compounds described herein, are disclosed.... Agent: Synta Pharmaceuticals Corp.

20130035387 - Sarms and method of use thereof: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.... Agent: University Of Tennessee Research Foundation

20130035389 - Methods for treating myelodysplastic syndrome with ezatiostat: This invention relates to methods, assays, devices and systems for identifying patients having a myelodysplastic syndrome for treatment with ezatiostat or a salt thereof, or evaluating the patient's response possibility to the treatment by measuring and evaluating the patient's gene expression profile. This invention also relates to methods of treating... Agent: Telik, Inc.

20130035388 - Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex: This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where... Agent:

20130035390 - Treatment of multiple sclerosis: Disclosed are methods for treating multiple sclerosis patients that entail co-administration of effective amounts of a Ras antagonist which is farnesylthiosalicylic acid or an analog thereof, and a second active agent selected from glatiramer acetate, laquinimod and combinations thereof. Therapeutic compositions and methods of making them are also disclosed.... Agent: Ramot At Tel-aviv University Ltd.

20130035391 - Felbinac-containing transdermally absorbable preparation: An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing... Agent: Teikoku Seiyaku Co., Ltd.

20130035392 - Selective inhibition of the membrane attack complex of complement and c3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex: It pertains to selective inhibition of C3 convertase of the alternative pathway of complement as well as the previously claimed assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It... Agent:

20130035393 - Method for treating schizophrenia: The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative.... Agent: Sucampo Ag

20130035394 - Calixarene-based peptide conformation mimetics, methods of use, and methods of making: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.... Agent: Regents Of The University Of Minnesota

20130035395 - Water-based cosmetic and manufacturing method thereof: A water-based cosmetic that includes: (A) ceramidic compound-containing particles that include a ceramidic compound and that are dispersed as an oil phase in an aqueous phase; (B) a fatty acid component composed of at least one selected from the group consisting of fatty acids and fatty acid salts; and (C)... Agent: Fujifilm Corporation

20130035396 - Antimicrobial cleansing compositions: Antimicrobial cleansing compositions are disclosed. The cleansing compositions include thin liquid/foaming compositions and gels. The antimicrobial cleansing compositions are effective antimicrobials and safe for everyday use.... Agent: Kimberly-clark Worldwide, Inc.

20130035397 - Anti-viral compounds: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.... Agent: Kineta, Inc.

20130035398 - Functionalized fullerenes as a biomass stimulant and a life extension agent: Methods of stimulating an increase in biomass by stimulating the growth, lifespan and/or reproduction of organisms such as fungi, algae, plants, and other aquatic organisms are provided by applying an effective amount of functionalized fullerenes. For example, polyhydroxy fullerenes are effective at low levels of promoting the increase in biomass.... Agent: University Of Florida Research Foundation, Inc.

20130035399 - Marked inorganic additives: The subject matter of the present invention is marked inorganic additives, a method for their production and also their use.... Agent: Sachtleben Chemie Gmbh

20130035400 - Metal effect pigments coated with sio2, method for producing said metallic effect pigments and use: The invention relates to a method for coating metallic effect pigments with silicon oxide, in which alkoxysilane(s) and/or silicon halide(s) in organic solvent are reacted with water in the presence of metallic effect pigments, where the reaction includes at least two steps, where (a) the reaction is carried out with... Agent: Eckart Gmbh

20130035402 - Bioabsorbable polyesteramides and uses thereof: Novel biodegradable polyesteramides derived from optionally functionalized diacids and optionally functionalized diamines or from compounds having both optionally functionalized acid and optionally functionalized amine moieties, their preparation, and absorbable surgical articles fabricated therefrom, such as monofilament and multifilament sutures, films, sheets, plates, clips, staples, pins, screws, stents, stent coatings, packaging... Agent: Bezwada Biomedical, LLC

20130035401 - Novel self-reversible reverse latex, and use thereof as a thickening agent in a cosmetic composition: A self-reversible reverse latex, and its use as a thickener. The self-reversible reverse latex includes: 50%-70% of a cross-linked polyelectrolyte obtained by the polymerization of a monomer of formula (I), with R1 being 8 to 20 carbon atoms and 1≦n≦30 for a neutral monomer, and a monomer having an acid... Agent: Societe Dexploitation De Products Pour Los Industr Chimique Seppic

20130035403 - Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids: The invention relates to cells, nucleic acids, and enzymes, the use thereof for producing sophorolipids, and methods for producing sophorolipids.... Agent: Evonik Degussa Gmbh

20130035404 - Integrated analyses of breast and colorectal cancers: Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated... Agent: The Johns Hopkins University